high mobility group box 3 pseudogene 22Genealiases: []
Q-omics provides the consensus-scored HMGB3P22 profile across patient tissues and cancer cell-line models. HMGB3P22 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HMGB3P22 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, HMGB3P22 RNA expression shows 12,886 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where HMGB3P22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB3P22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB3P22 survival associations across molecular data types. HMGB3P22 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB3P22 RNA expression–survival associations across cancer types. High HMGB3P22 expression shows unfavorable associations in UCEC, but favorable associations in HNSC, OV, LGG, SKCM and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for HMGB3P22 RNA expression.
This table summarizes HMGB3P22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB3P22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB3P22 shows lower tumor expression in HNSC, UCEC, THCA and COAD and higher tumor expression in LIHC and KIRC. The HNSC box plot shows higher HMGB3P22 RNA expression in normal versus tumor tissue (log2 FC = −0.293, t-test p < 0.001).
This table shows molecular features associated with HMGB3P22 in patient tissues and cancer cell lines. In patient samples, HMGB3P22 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
